Immuron Limited  (IMRN)
Other Ticker:  
Price: $2.8514 $-0.14 -4.635%
Day's High: $2.89 Week Perf: 7.2 %
Day's Low: $ 2.80 30 Day Perf: -24.96 %
Volume (M): 11 52 Wk High: $ 5.96
Volume (M$): $ 32 52 Wk Avg: $2.03
Open: $2.88 52 Wk Low: $1.48

 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 22
 Capital Exp. (TTM) (Millions $) 0

Immuron Limited
Immuron Limited is a biopharmaceutical company that develops and commercializes oral immunotherapeutics for the treatment and/or prevention of various diseases and infections. The company's products are designed to target and improve the gut microbiome, which plays a crucial role in maintaining overall health. Immuron's lead product, Travelan, is a travel vaccine that helps prevent and treat travelers' diarrhea caused by E. coli and other bacteria. Additionally, the company is also involved in developing other immunotherapeutic products for the treatment of C. difficile infection, non-alcoholic steatohepatitis (NASH), and liver diseases. Immuron Limited is headquartered in Melbourne, Australia, and works to advance its products through clinical trials and commercialization partnerships.

   Company Address: Level 3, 62 Lygon Street Victoria 3053
   Company Phone Number: 3 9822 7735   Stock Exchange / Ticker: NASDAQ IMRN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Immuron Limited

Immuron Limited reports decreased revenue and widened net loss in Q4 2023

In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.


Immuron Limited's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com